Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Moderna to Present at the Jefferies 2022 London Healthcare Conference

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m.

Why Moderna Stock Could Still Be More Than 50% Overvalued

Moderna (NASDAQ: MRNA) took the world by storm in 2020. The company quickly became a leader in the race to develop COVID-19 vaccines. Since the middle of last year, though, Moderna has been through storms of its own.

The 7 Best Pharma Stocks to Buy Now

Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks.

Moderna Inc. stock rises Tuesday, still underperforms market

Shares of Moderna Inc. inched 0.35% higher to $164.61 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...

Patent wars: Moderna’s battle for the spoils of Covid vaccines

In autumn 2020, as drugmakers raced to get vaccines to market in the face of the biggest public health crisis in a generation, Moderna made a bold pledge: it would not enforce its patents against rivals developing Covid-19 jabs. This year, however, almost two years after Pfizer and BioNTech beat it to the first approved mRNA jab, Moderna fired back with a lawsuit over patents for a technology that could open the door to many more vaccines. If Moderna wins, it could gain a slice of billions of dollars in revenues from the BioNTech/Pfizer Covid jab.

Why Moderna Stock Jumped on Monday

Durable coronavirus stock Moderna (NASDAQ: MRNA) rose by over 3.5% in price on Monday, nearly quadrupling the percentage gain of the S&P 500 index on the day. The move followed news that the company racked up yet another approval from a healthcare authority for a new booster version of its Spikevax coronavirus vaccine. Late Friday after market hours, Moderna announced that the second of its two bivalent booster vaccines targeting the coronavirus had been authorized for use in Canada.

7 Cheap Penny Stocks To Buy For Under $1 Right Now

Penny stocks under $1: Are they worth the risk to buy right now?

Moderna Inc. stock outperforms market on strong trading day

Shares of Moderna Inc. rose 3.55% to $164.04 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...

BioNTech earnings drop but forecast for vaccine income grows

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Moderna price target lowered to $186 from $188 at Chardan

Chardan analyst Geulah Li... MRNA